Pfizer (NYSE:PFE) Trading Down 0.1%

Pfizer Inc. (NYSE:PFE) was down 0.1% during mid-day trading on Wednesday . The stock traded as low as $29.31 and last traded at $29.46. Approximately 7,065,725 shares changed hands during trading, a decline of 82% from the average daily volume of 39,574,223 shares. The stock had previously closed at $29.50.

Analyst Ratings Changes

A number of analysts have commented on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Morgan Stanley boosted their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Barclays raised their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, July 10th. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $34.50.

Pfizer Stock Up 1.6 %

The firm’s 50 day simple moving average is $28.45 and its two-hundred day simple moving average is $27.73. The firm has a market cap of $169.88 billion, a price-to-earnings ratio of -497.92, a PEG ratio of 1.16 and a beta of 0.69. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same period in the previous year, the company posted $1.23 earnings per share. The firm’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, equities analysts forecast that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.60%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s payout ratio is currently -2,799.53%.

Institutional Investors Weigh In On Pfizer

Several institutional investors and hedge funds have recently bought and sold shares of the company. Olistico Wealth LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at $29,000. Creekmur Asset Management LLC bought a new position in shares of Pfizer in the 4th quarter valued at $32,000. Trivant Custom Portfolio Group LLC raised its holdings in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in shares of Pfizer during the 4th quarter worth $36,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.